• There are no suggestions because the search field is empty.

The European Parliament adopts proposed amendment to Medical Devices Regulation 2017/745 (MDR) to extend transitional deadlines for legacy Medical Devices 

Author Avatar
Vincent Van Fulpen, Life Sciences Consultant at QbD Group
Regulatory Affairs
Medical Devices

The European Parliament has approved a proposal to extend the transitional deadlines for certain medical devices under the MDR to ensure availability of devices whose certificates have expired or will expire before 26 May 2024. Manufacturers must adhere to specific conditions to comply with the new transition periods. Learn more here.

The European Parliament adopts proposed amendment to Medical Devices Regulation 2017/745 (MDR) to extend transitional deadlines for legacy Medical Devices | QbD Group
4:06

 
The European Parliament has adopted the proposal to extend the transitional period for legacy devices (i.e. those covered by a certificate or declaration of conformity issued under Council Directives 90/385/EEC or 93/42/EEC before the date of application (DOA) of the MDR 2017/745, May 26th, 2021. The goal of this extension is to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework.
 
However, it’s important to note that they also set specific conditions manufacturers need to adhere to. We made an overview of the extended transition periods and listed the conditions that need to be fulfilled.
 

Extended transition periods

Conditions that already applied

  1. The device continues to comply with MDD 93/42/EEC or AIMDD 90/385/EEC, as applicable;
  2. There are no significant changes in the design and intended purpose;
  3. The requirements of MDR relating to post-market surveillance, market surveillance, vigilance, registration of economic operators and of devices shall apply.

New conditions

  1. The device does not present an unacceptable risk to the health or safety of patients, users or other persons, or to other aspects of the protection of public health;
  2. No later than 26 May 2024, the manufacturer has put in place a MDR 2017/745 compliant quality management system;
  3. No later than 26 May 2024, the manufacturer or the authorised representative has lodged a formal application with a notified body for conformity assessment in respect of the legacy device or in respect of a device intended to substitute that legacy device; No later than 26 September 2024, the notified body and the manufacturer have signed a written agreement. Meaning the notified body becomes responsible for surveillance of the legacy devices.
 
 

Extension of validity of certificates 

MDD 93/42/EEC or AIMDD 90/385/EEC certificates that were valid on the date of application (DOA) of the MDR (May 26th 2021) can be placed on the market until the dates outlined in the table if all above conditions are met.

MDD 93/42/EEC or AIMDD 90/385/EEC certificates that already expired before this amendment comes into force have an additional condition to fulfil. They remain valid until the dates outlined in the table above only if one of the following additional conditions is fulfilled:

  1. Before the expiry date of the certificate the manufacturer and a notified body have signed a written agreement for the conformity assessment in respect of the device covered by the expired certificate or in respect of a device intended to substitute that device OR
  2. A competent authority has granted a derogation from the applicable conformity assessment procedure (article 59(1)), or has required the manufacturer to carry out the applicable conformity assessment procedure (article 97(1)).
Furthermore, the ‘sell-off’ date is removed. This deletion applies to both medical devices and IVDs. The ‘sell-off’ date is the end date after which devices that have already been placed on the European market, and remain available for purchase, should be withdrawn. Removing this ‘sell-off’ date will ensure that safe and essential medical devices that are already on the European market remain available to healthcare systems and to patients in need.
 
 
This amendment gives Notified Bodies more time to assess the conformity of MDD and AIMDD devices while manufacturers can continue placing their legacy devices on the market. Manufacturers however, still need to have their QMS and Technical Documentation compliant with MDR requirements before 26 May 2024. As this is the date they need to provide the Technical Documentation to the notified body as part of the formal application for conformity assessment.
 

Stay ahead in life sciences

Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.

Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.

Circles-banner-short

Discover more expert content

preview_image
Case study

A Decade of Excellence: Linguistic Review Support for a Global Pharma Leader​

QbD Group streamlines linguistic reviews for a leading pharma client, ensuring compliance and accuracy across 25 EU/EEA languages while meeting stringent regulatory deadlines.
preview_image
Whitepaper

Medical Device Regulation (MDR) Checklist

Implement the Medical Device Regulation (MDR) with ease. Download our checklist of mandatory documents for MDR compliance.
preview_image
Whitepaper

Regulatory Affairs for Pharma and Biotech

In this flyer, you will learn more about the regulatory services QbD Group provides for the pharmaceutical and biotechnology industries.
preview_image
Whitepaper

Clinical Evaluation for Medical Devices under MDR

This whitepaper will guide you through crucial regulatory documents pertaining to the clinical evaluation process of your medical device. Download now!
preview_image
Whitepaper

IVDR extension: what does this mean for you?

In this whitepaper, you will learn the impact of the IVDR transition extension and receive tips and strategies to navigate these regulatory changes.
preview_image
Webinar

Drug-Device Combination Products and Article 117

Explore the regulatory complexities of Drug-Device Combination Products. Learn about Article 117 requirements, Notified Body Opinions, and more.
preview_image
Whitepaper

Mobile health on the rise: exploring the regulatory landscape for reimbursement

This whitepaper will help you navigate the maze of the DTx regulatory environment, highlighting several important countries and regulations.
preview_image
Whitepaper

Clinical investigations under MDR: key insights and practical experiences

This whitepaper covers clinical investigation authorization under MDR, the EU Legal Representative's role, and the MDR's impact on study conduct and post-market surveillance.
preview_image
Case study

CE Mark Renewal for bioXtra Products: A Success Story

Discover how Lifestream Pharma successfully renewed the CE mark for their BioXtra Dry Mouth products under the EU MDR. Learn about the challenges faced, the approach taken for compliance, and the results achieved.
preview_image
Webinar

Technical Documentation Essentials for Medical Device Software

Gain practical insights on crafting MDR-compliant technical documentation for Medical Device Software.
preview_image
Webinar

Getting Started: Overcoming Initial Obstacles in Medical Device Software Development

Watch our webinar on demand and learn about regulatory obstacles, MDR, AI Act, and best practices for medical device software development and market entry.
preview_image
Webinar

Mastering Clinical Performance Studies under IVDR

In the evolving regulatory landscape of IVDs, demonstrating clinical performance is more crucial and challenging than ever. Discover more in this webinar on demand.
preview_image
Whitepaper

Clinical evidence for In Vitro Diagnostics under IVDR

In this whitepaper, we will guide you through the documents required for the demonstration of clinical evidence under the IVDR. Download now.
preview_image
Webinar

Post-Market Surveillance Requirements for Medical Devices and IVDs

Learn about post-market surveillance requirements under MDR and IVDR regulations. Gain insights from industry experts in this on-demand webinar.
preview_image
Whitepaper

The key role of Regulatory Affairs in the pharmaceutical industry: from drug development to commercialization

Discover the key role of Regulatory Affairs in pharma and how Regulatory Affairs teams support product lifecycle management in this whitepaper. Download now.
preview_image
Webinar

3D Printing in the Healthcare World

Explore the challenges and opportunities of 3D printing in healthcare, featuring expert insights on regulations, pitfalls, and efficiency.
preview_image
Webinar

IVDR Extension Explained: Tips & Strategies

Gain valuable insights on the IVDR extension and its impact on IVD manufacturers with our webinar on demand.
preview_image
Whitepaper

Innovations in ATMP: state of the industry in 2024

This whitepaper explores the innovations in ATMP and solutions in detail, with a focus on the current landscape as of April 2024. Download now.
preview_image
Case study

The journey toward IVDR compliance for the LVOne device

QbD Group helped Upfront Diagnostics gain entry into the MD/IVD industry by supporting them on their path to ISO 13485 certification.
preview_image
Case study

Ensuring a smooth MDR transition for Oystershell's medical devices

The landscape of medical device regulations is constantly evolving, making it a challenge for companies to keep up. Our collaboration with Oystershell, which began in July 2023, highlights our expertise in transforming complex challenges into success stories, all with a touch of QbD Clinical magic.
preview_image
Case study

Successful clinical evaluation supports rapid CE marking of Minze Health's Uroflowmeter

QbD Clinical assisted Minze Health, a urology-focused medical devices company, in obtaining CE marking under MDR through clinical evaluation.
preview_image
Webinar

The Medical Device CE Certification Pathway Explained: From Classification to Conformity Assessment by the Notified Body

Learn about the Medical Device CE Certification Pathway, from classification to conformity assessment by a Notified Body. Join our webinar on demand.
preview_image
Case study

Helping Relu to comply with changing regulations

QbD Group supported software company Relu with their expertise to comply with changing regulations.
preview_image
Case study

Quickly bringing a new COVID-19 medical device to market

Obtaining the required government certifications for a medical device is always a challenge. Especially when the COVID clock is ticking.